相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Neeta Somaiah et al.
CLINICAL CANCER RESEARCH (2019)
TCR-like antibodies in cancer immunotherapy
Qinghua He et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+effector T cells.
Tiphaine Delaunay et al.
ONCOIMMUNOLOGY (2018)
Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy
Olga Gordeeva
SEMINARS IN CANCER BIOLOGY (2018)
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer
J. Brian Szender et al.
GYNECOLOGIC ONCOLOGY (2017)
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2016)
NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers
Yoko Oshima et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma
Richard G. Everson et al.
NEURO-ONCOLOGY (2016)
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma
Nathan Singh et al.
ONCOIMMUNOLOGY (2016)
Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance
Christopher J. Nirschl et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
Wei Xue et al.
ONCOIMMUNOLOGY (2016)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope
P. Baumgaertner et al.
ONCOIMMUNOLOGY (2016)
LV305, a dendritic cell-targeting integration-deficient ZVex™-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response
Tina Chang Albershardt et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg et al.
NATURE REVIEWS CANCER (2016)
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Deepa K. Krishnadas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX (TM) vaccine in patients with advanced melanoma
Oliver Klein et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
New York esophageal squamous cell carcinoma-1 and cancer immunotherapy
Ali Esfandiary et al.
IMMUNOTHERAPY (2015)
Landscape of Tumor Antigens in T Cell Immunotherapy
Sadia Ilyas et al.
JOURNAL OF IMMUNOLOGY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Morten F. Gjerstorff et al.
ONCOTARGET (2015)
The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells
Madhav Sharma et al.
Journal for ImmunoTherapy of Cancer (2015)
Treatment with 5-Aza-2′-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
Agnes S. Klar et al.
PLOS ONE (2015)
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
Tim Luetkens et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1-or Melan-A-Specific T Cells
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2014)
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
Z. K. Klippel et al.
GENE THERAPY (2014)
Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma
Phyu P. Aung et al.
HUMAN PATHOLOGY (2014)
Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer
Simon Laban et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Design of a Novel Integration-deficient Lentivector Technology That Incorporates Genetic and Posttranslational Elements to Target Human Dendritic Cells
Semih U. Tareen et al.
MOLECULAR THERAPY (2014)
Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens
Stephen J. Hayes et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer
Yan-Yan Long et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2014)
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
Dimitrios Balafoutas et al.
BMC CANCER (2013)
NY-ESO-1 antibody as a novel tumour marker of gastric cancer
S. Fujiwara et al.
BRITISH JOURNAL OF CANCER (2013)
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
P. C. Schuberth et al.
GENE THERAPY (2013)
Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
Nancy E. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma
Tvrtko Hudolin et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2013)
NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2013)
Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein
Nobukazu Komatsu et al.
MOLECULAR IMMUNOLOGY (2013)
HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression
Pierre-Francois Cartron et al.
MOLECULAR ONCOLOGY (2013)
NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches
Gilson S. Baia et al.
CANCER IMMUNOLOGY RESEARCH (2013)
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Seth M. Pollack et al.
CANCER (2012)
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis
Jin-Ping Lai et al.
MODERN PATHOLOGY (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™
Theo Nicholaou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Translating Tumor Antigens into Cancer Vaccines
Luigi Buonaguro et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers
Yao-Tseng Chen et al.
PLOS ONE (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact
James E. Talmadge
SEMINARS IN CANCER BIOLOGY (2011)
The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination
Iana Parvanova et al.
VACCINE (2011)
Strategies for Cancer Vaccine Development
Matteo Vergati et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
Julien Fourcade et al.
JOURNAL OF IMMUNOLOGY (2009)
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
Luiz Gonzaga Almeida et al.
NUCLEIC ACIDS RESEARCH (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
Richard W. Griffiths et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development
Morten F. Gjerstorff et al.
HUMAN REPRODUCTION (2007)
The suppression of delayed-type hypersensitivity by CD8(+) regulatory T cells requires interferon-gamma
Robert E. Cone et al.
IMMUNOLOGY (2007)
Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma
Shinichiro Nakamura et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2006)
Tumor antigen expression in melanoma varies according to antigen and stage
C Barrow et al.
CLINICAL CANCER RESEARCH (2006)
Directions in the immune targeting of cancer: Lessons learned from the cancer-testis AgNY-ESO-1
Theo Nicholaou et al.
IMMUNOLOGY AND CELL BIOLOGY (2006)
Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters
JR Peng et al.
CANCER LETTERS (2005)
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis
B Kubuschok et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
Y Sugita et al.
CANCER RESEARCH (2004)
Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments
G Held et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
QY Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
NY-ESO-1 protein expression and humoral immune responses in prostate cancer
A Fosså et al.
PROSTATE (2004)
Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: Expression and humoral response to NY-ESO-1
M Maio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
RPM Sutmuller et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
JS Goydos et al.
JOURNAL OF SURGICAL RESEARCH (2001)
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Induction of primary NY-ESO-1 immunity:: CD8+T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers
E Jäger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma
P Gibbs et al.
MELANOMA RESEARCH (2000)
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma
E Jäger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9
MJ Scanlan et al.
CANCER LETTERS (2000)
分享论文
